Alkermes stock rating upgraded by RBC Capital on narcolepsy drug potential
PositiveFinancial Markets

Alkermes has received an upgraded stock rating from RBC Capital, driven by the promising potential of its narcolepsy drug. This upgrade is significant as it reflects growing confidence in the company's ability to address a critical health issue, potentially leading to increased investor interest and market performance. The advancement in treatment options for narcolepsy could also improve the quality of life for many patients, making this news particularly impactful.
— Curated by the World Pulse Now AI Editorial System